Halyard Health, Inc. Announces Third Quarter 2017 Results, Raises Full-Year Adjusted Diluted EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Halyard Health (HYH) Misses Q3 EPS by 11c, Lifts FY EPS Guidance
November 1, 2017 7:05 AM EDTHalyard Health (NYSE: HYH) reported Q3 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $401.4 million versus the consensus estimate of $396.06 million.
GUIDANCE:
Halyard Health sees FY2017 EPS of $2.03-$2.13, versus the consensus of... More
Halyard Health (HYH) to Sell S&IP Business to Owens & Minor (OMI) for $710M
November 1, 2017 7:03 AM EDTHalyard Health, Inc. (NYSE: HYH) today announced it has entered into a definitive agreement with Owens & Minor, Inc. (NYSE: OMI) to sell its Surgical and Infection Prevention ("S&IP") business for $710 million. S&IP provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
The divestiture of the S&IP business accelerates Halyard's transformation into a pure-play medical devices business, with market leading positions in its core franchises of pain management and chronic care. As a growth-oriented business with a singular focus... More
